Showing results (181-190 of 297) with videos related to
Sort By:
Pageof 30
Breast Cancer Research and Treatment|February 25, 2010
Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriersSusan M Domchek, Tara M Friebel, Judy E Garber, et al.Gynecologic Oncology|August 22, 2024
Incidence of endometrial cancer in BRCA mutation carriersJoanne Kotsopoulos, Jan Lubinski, Tomasz Huzarski, et al.Gynecologic Oncology|August 10, 2025
Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variantAdriana I Apostol, Joanne Kotsopoulos, Jacek Gronwald, et al.Breast (Edinburgh, Scotland)|January 26, 2023
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancerArlene Chan, Manuel Ruiz-Borrego, Gavin Marx, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2014
Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutationAmy P M Finch, Jan Lubinski, Pål Møller, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2014
The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancerMartin Filipits, Torsten O Nielsen, Margaretha Rudas, et al.European Journal of Cancer (Oxford, England : 1990)|January 2, 2023
Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12Ana-Alicia Beltran-Bless, Mark J Clemons, Christian Fesl, et al.Breast Care (Basel, Switzerland)|June 16, 2022
Influence of Height on Risk and Outcome of Patients with Early Breast Cancer: A Pooled Analysis of 4,925 Patients from 5 Randomized Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)Simon P Gampenrieder, Magdalena Pircher, Christian Fesl, et al.Breast Cancer Research and Treatment|June 22, 2014
Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriersJacek Gronwald, Andre Robidoux, Charmaine Kim-Sing, et al.Lancet (London, England)|June 5, 2015
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trialMichael Gnant, Georg Pfeiler, Peter C Dubsky, et al.Pageof 30